JP2003325565A - Condom, lubricant for condom, and therapeutic agent for preventing chlamydia infection - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a condom which can safely and effectively prevent a Chlamydia infection, a condom lubricant, and a therapeutic agent. <P>SOLUTION: The condom coated with a tropolone compound is provided. The tropolone compound is effective for Chlamydia and therefore even in the case the effect of preventing sexual infectious deseases based on the structure of the condom, such as a failure and detachment of the condom, cannot be achieved, the Chlamydia infection can be effectively prevented. <P>COPYRIGHT: (C)2004,JPO

Description

Detailed Description of the Invention

[0001]

TECHNICAL FIELD The present invention relates to a condom and a lubricant for a condom. In particular, the present invention relates to condoms and condom lubricants that can prevent Chlamydia infections. The present invention also relates to a prophylactic / therapeutic agent for Chlamydia infection.

[0002]

2. Description of the Related Art The spread of sexually transmitted diseases has become a serious problem all over the world, and the number of young people infected in Japan is increasing. In recent years, Neisseria gonorrhoea, which has been conventionally known as a sexually transmitted disease,
Gonorrhea caused by e, Treponema pallid
In addition to infectious diseases such as syphilis caused by um, Herpe
genital herpes caused by s simplex virus, acupuncture condyloma caused by Human papilloma virus, Human immunod
infectious diseases such as acquired immunodeficiency syndrome (AIDS) caused by efficiency virus, and Chla
mydia trachomatis (hereinafter, C. tr
Chlamydia infections due to A. chomatis) have a marked increase. In particular, Chlamydia infection has become a major infectious disease which accounts for more than half of today's sexually transmitted diseases in Japan. Although Chlamydia infections have extremely mild symptoms, they often occur over a long period of time as a subclinical infection that lacks subjective symptoms, and they can be a secondary source of infection to partners and newborns. May cause serious problems. Furthermore, there is a serious problem that the probability of being infected with the AIDS virus is high when a person has a Chlamydia infection.
Moreover, although oral sex has become popular in recent years, chlamydia also causes a problem that oral sex also infects the pharynx and the oral cavity, which causes further infection.

[0003] Chlamydia infection is caused by contact between the infected person's blood, semen, vaginal secretions, etc., including chlamydia and / or chlamydia-infected cells, and the mucous membrane of the infected person during sexual activity. It is very effective to use a condom as a method for preventing infection.

[0004]

However, since the condom is used in an amorphous state, it sometimes breaks depending on the method of use, and the condom is left in the inserted state after sexual intercourse. It is also possible that condoms may not be able to prevent chlamydial infections if proper use is not achieved, such as the natural loss of the. In such a case, C. which is the causative bacterium of chlamydia infection. If a drug that prevents the infection of trachomatis is applied to the contact site between blood, semen, vaginal secretions, etc. and the mucous membrane, the possibility of infection is expected to be reduced. In the treatment of chlamydia infection, oral administration of tetracycline, doxycycline, minocycline, clarithromycin, ofloxacin and the like is performed. However, given that it is applied prophylactically each time sexual intercourse is taken, it is not preferable to prophylactically apply these therapeutic agents to the mucosal part from the viewpoint of safety to the human body. Therefore, a compound that does not cause side effects even when repeatedly applied to the mucous membrane part of the human body for a long time and is effective against chlamydia infection is desired.

The present inventors have found that tropolone compounds such as hinokitiol are particularly effective in preventing and treating chlamydia infection. The present invention was made based on this finding, and an object of the present invention is to provide a condom that is highly safe for the human body and that can effectively prevent chlamydia infection. Further, the present invention is
It is an object of the present invention to provide a condom lubricant that is highly safe for the human body and can effectively prevent Chlamydia infection. Another object of the present invention is to provide a prophylactic / therapeutic agent for chlamydia infection, which is highly safe for the human body and can effectively treat and / or prevent chlamydia infection.

[0006]

The present invention provides, as claim 1, a condom coated with a tropolone compound. The present invention provides, as claim 2, a condom which is extracted from a tree and is coated with an acidic oil component containing a tropolone compound. The present invention provides, as claim 3, the condom according to claim 1 or 2, wherein the tropolone compound is one or more compounds selected from the group consisting of hinokitiol, β-drabulin and γ-tsuyaprisin. The present invention provides, as claim 4, a condom coated with Hiba oil. The present invention provides, as claim 5, a condom lubricant containing a tropolone compound. The present invention provides, as claim 6, a lubricant for a condom, which contains an acidic oil component containing a tropolone compound extracted from a tree. The present invention provides, as claim 7, the condom lubricant according to claim 5 or 6, wherein the tropolone compound is one or more compounds selected from the group consisting of hinokitiol, β-drabulin and γ-tsuyaprisin. The present invention provides, as Claim 8, a lubricant for a condom, which contains Hiba oil. The present invention provides, as claim 9, a prophylactic / therapeutic agent for chlamydia infection, which comprises a tropolone compound as an active ingredient.

[0007]

DETAILED DESCRIPTION OF THE INVENTION One aspect of the invention is a condom coated with a tropolone compound. Another aspect of the present invention is a condom lubricant containing a tropolone compound. Still another embodiment is a prophylactic / therapeutic agent for chlamydia infection containing a tropolone compound as an active ingredient. In the present invention, the term "tropolone compound" means a compound of the formula

[Chemical 1] [Wherein R ¹ , R ² , R ³ , R ⁴ and R ⁵ are each independently hydrogen or a linear or branched alkyl, alkenyl or alkynyl group]. Preferably, the tropolone compound has a R ¹ ,
R ² , R ³ , R ⁴ and R ⁵ are each independently hydrogen or linear or branched (C ₁ -C ₆ ) alkyl, (C ₂ -C ₆ ) alkenyl, and (C ₂ −
C ₆ ) alkynyl. More preferably, any one of R ¹ , R ² , R ³ , R ⁴ and R ⁵ is linear or branched (C ₁ -C ₆ ) alkyl, (C ₂ -C ₆ ) alkenyl, or _(C 2 _-C 6)
Alkynyl groups are compounds in which the remaining four are hydrogen. Even more preferably, either R ² or R ³ is straight or branched (C ₁ -C ₆ ) alkyl,
A _(C 2 -C ₆₎ alkenyl or _(C 2 -C ₆₎ alkynyl group, a compound remainder are hydrogen. Also preferred is a compound in which either R ² or R ³ is linear or branched C ₃ alkyl or C ₃ alkenyl, the remainder being hydrogen. Further, preferably, any one of R ¹ , R ² , R ³ , R ⁴ and R ⁵ is isopropyl or isopropenyl,
The remaining four are compounds that are hydrogen. More preferred are compounds where either one of R ² or R ³ is isopropyl or isopropenyl and the remainder is hydrogen. Most preferably, the tropolone compound is hinokitiol, β-drabulin or γ-tsuyaprisin.

In the present invention, the tropolone compound is
It may be in the form of the above compound or in the form of a salt of the tropolone compound. The salt of the tropolone compound can be any salt, for example, iron complex salts such as hinokitiin which is an iron complex salt of hinokitiol, and also copper complex salt, manganese complex salt, aluminum complex salt, magnesium complex salt, calcium complex salt, barium complex salt. , Zinc complex salt, silver complex salt, sodium salt and the like, but are not particularly limited. In addition, covering the condom,
Alternatively, the tropolone compound contained in the lubricant for condom or the preventive / therapeutic agent for chlamydia infection may be one type of compound or two or more types of compounds. Further, it may be a single salt or plural kinds of salts.

The tropolone compound in the present invention may be obtained from any source, and may be a compound produced by chemical synthesis or may be a compound extracted from a natural product. When the tropolone compound extracted from a natural product is used as a condom coating or a lubricant for a condom, the tropolone compound may be a pure product purified after extraction, or a mixture of a plurality of tropolone compounds, Further, it may be a mixture containing a compound other than the tropolone compound. When the tropolone compound is extracted from a natural product, the source natural product is not particularly limited as long as it is a natural product containing the tropolone compound, and examples thereof include trees. Preferably, the tree from which the tropolone compound is extracted includes, but is not limited to, Aomori Hiba, Taiwan Hinoki, Asunaro and Western Red Cedar.

An extract containing a tropolone compound can be obtained by subjecting a natural product such as the above tree to an extraction treatment. As this extraction treatment method, any known extraction method can be applied. Examples of the method include, but are not limited to, a steam distillation method, a hot water distillation method, an oil and fat adsorption extraction method, and an organic solvent extraction method. Preferably, the extraction treatment method is a steam distillation method. When the above tree is extracted by these methods, the tropolone compound is mainly
It is contained in the acidic oil in the extract. Therefore, in the present invention, the tropolone compound is “extracted from a tree,
As an acidic oil containing a tropolone compound ", it can be applied to condoms or condom lubricants. Preferably, the tree-derived extract containing the tropolone compound is hiba oil.

In the present invention, the condom includes not only a male condom for wearing on a male reproductive organ but also a female condom for attaching on a female reproductive organ. Further, the condom of the present invention may be any condom of known material and shape, and is not particularly limited. Moreover, the lubricant for condom in the present invention is not particularly limited as long as it is a lubricant applicable to a condom, and for a condom made of any known material such as water-based gel and silicone oil. Lubricants may be mentioned. Further, the lubricant for condom may be a lubricant applied at the same time when the condom is individually packaged, or may be a lubricant applied to the condom during sexual intercourse.

The condom of the present invention is coated with a tropolone compound, but the coating here only needs to cover at least a part of the condom, and does not need to cover the entire surface of the condom. Further, the coating may be a mode in which only one side is covered, such as the inside or outside of the condom, or a mode in which both the inside and outside of the condom are covered. From the viewpoint of preventing sexually transmitted diseases, it is preferable that both the inside and outside of the condom are covered. As the coating method, any method can be used as long as it can coat the condom with the tropolone compound, and examples thereof include coating, spraying, dipping, and drip infusion, but are not limited thereto. Further, as the tropolone compound, it is possible to apply to the condom in any manner, but since the condom can be provided with lubricity at the same time as the coating of the tropolone compound,
More preferably, it is coated with a water-soluble gel containing a tropolone compound or a condom lubricant such as silicone oil. Further, after coating the condom with the tropolone compound, a lubricant containing no tropolone compound may be applied. A condom manufactured by a conventional method, for example, after the manufacturing and inspection steps, peeled from the mold, dropped the solution containing the tropolone compound onto the rolled up condom, and film-wrapped it to cover the entire surface with the tropolone compound. It will be in the state of being. When a condom lubricant containing a tropolone compound is used, a condom of the type having lubricity can be manufactured.

As the lubricant for condom, any substance that gives lubricity to a condom is used, for example, polyhydric alcohol, sugar alcohol, and other viscous substances are used, but not limited thereto. For example, polyhydric alcohols include glycerin, propylene alcohol,
Examples include glycols such as diethylene alcohol and polyglycols, and examples of sugar alcohols include maltitol and sorbitol. Other viscous substances include alginic acid or its sodium salt, potassium salt,
Examples include natural viscous substances such as gelatin, as well as synthetic viscous substances such as carboxymethyl cellulose. The kind and addition amount of these substances that provide lubricity are appropriately selected so as not to interfere with the antibacterial and antiviral effects of the tropolone compound, and based on the effect on the condom surface, workability, and the like. These substances make it possible to adjust the viscosity of the lubricant for condoms containing the tropolone compound of the present invention, and further enable excellent wet coating. Further, other compounds such as a fragrance, a pigment, a humectant, and an antiseptic can be further mixed as long as the object of the present invention is not impaired.

The agent for preventing and / or treating chlamydia infection according to the present invention can adopt any known dosage form and is not particularly limited. However, from the viewpoint of being directly applicable to an affected area, any known dosage form is known. It is preferable that it is in the form of an external preparation. Examples of the external preparation include, but are not limited to, ointments, tapes, effervescent tablets, vaginal suppositories, and jellies.

The amount of the tropolone compound used in the condom of the present invention per condom is not particularly limited, but generally 0.0001 to 100.
mg, preferably 0.001 to 10 mg, and more preferably 0.01 to 1 mg. The content of the tropolone compound in the lubricant for condom of the present invention is not particularly limited, but is generally 10 mg /
mL-0.1 μg / mL, preferably 1 mg / mL-
1 μg / mL, more preferably 100 μg / mL to 1
It is 0 μg / mL. Further, the content of the tropolone compound in the agent for preventing and treating chlamydia infection of the present invention is not particularly limited, but is generally 10 mg / m 2.
L to 0.1 μg / mL, preferably 1 mg / mL to 1
μg / mL, more preferably 100 μg / mL to 10
μg / mL. Hereinafter, the present invention will be described in detail with reference to Examples, but the description of the Examples does not limit the scope of the present invention.

[0016]

Example 1 Evaluation of anti-Chlamydia action of tropolone compound after inoculation of Chlamydia to test cells The anti-Chlamydia action of test compounds was evaluated by the following procedures 1 to 8. 1. Human cervical cancer cell-derived HeLa229 cells were transferred to Ea
gle's Minimal Essential M
2.5 × 10 ⁵ (c) using edium (EMEM)
cells / mL) and then 24
-Dispense 1 mL / well of the cell suspension into a well plate and store it at 37 ° C, 5% CO ₂ for 24 hours.
Incubated for an hour to create a monolayer of HeLa229 cells. 2. The test compound was prepared at various concentrations using EMEM. 3. C. trachomatis (D / UW-3 / cx
Strain using EMEM at 1 × 10 ⁴ (IFU / m
L) was prepared. 4. 1 × 10 ⁴ on a monolayer of HeLa229 cells
(IFU / mL) C.I. trachomatis (D /
UW-3 / cx strain) solution was added at 0.2 mL per well and incubated for 120 minutes. 5. C. EMEM containing trachomatis was removed from the wells, and 1 mL of EMEM containing the test compound at various concentrations was added to each well. 6. The HeLa229 cell monolayer treated as described above was incubated for 3 days under the conditions of 37 ° C. and 5% CO ₂ . 7. Fluorescence (FITC)
C. using a Chlamydia fluorescence-labeled antibody (Chlamydia FA reagent: manufactured by Denka Seiken Co., Ltd.), which is a genus-specific monoclonal antibody against Chlamydia that is labeled with C. Inclusion bodies of Trachomatis were immunofluorescently stained. 8. For each well, the HeLa229 cell monolayer was observed by fluorescence microscopy and the number of inclusions in the 0.15 mm ² compartment was counted. This operation was performed at arbitrary 30 points per well. For each concentration of the test compound, the above-mentioned test was conducted in 4 wells, and for each of the 4 wells of the same concentration, a section of 0.15 mm ²
The number of inclusion bodies at 30 locations was counted and the total number of inclusion bodies counted in each of the four wells (ie, 0.
The number of inclusion bodies counted by observing 120 sections (total 18 mm ² ) in a section of 15 mm ² was calculated, and C.I. with the test compound in the test was calculated. trachomati
The infection prevention effect of s. Regarding the effect of the test compound, the number of inclusion bodies counted in the four wells by the above-mentioned method in the control group to which the test compound was not added, that is, a section of 0.15 mm ² and 120 sites were observed. The evaluation was also performed as a relative value when the total number of counted inclusion bodies was 100.

Hinokitiol (manufactured by Takasago International Co., Ltd.) was used as a test compound so that the final concentration during cell culture was 0 (control), 2, 4, 8, 16, and 32 μg / mL. The anti-Chlamydia effect was evaluated according to the evaluation method. The results are shown in Table 1.

[0018]

[Table 1]

As is clear from Table 1, hinokitiol was administered at a concentration of 2 μg / mL in a C. tra
In Hela cells infected with chomatis,
C. It had a therapeutic effect on the reduction of trachomatis. The minimum inhibitory concentration (MIC) at this time is 32 μg /
It was mL. That is, it was revealed that tropolone compounds such as hinokitiol are effective in treating chlamydia infection. Further, from the above results, when the tropolone compound is applied to the part where the cells infected with chlamydia during sexual activity are present, by decreasing the chlamydia in already infected cells present in the part, chlamydia It is expected to reduce the infection and have a therapeutic effect. Furthermore, it became clear that it is possible to prevent and reduce the infection of sexual partners with chlamydia caused by the reduction of these chlamydia-infected cells.

Example 2 Evaluation of anti-Chlamydia action of tropolone compound at the time of inoculation of Chlamydia to test cells The anti-Chlamydia action of the test compound was evaluated by the following procedures 1-8. 1. Human cervical cancer cell-derived HeLa229 cells were transferred to Ea
gle's Minimal Essential M
2.5 × 10 ⁵ (c) using edium (EMEM)
cells / mL) and then 24
-Dispense 1 mL / well of the cell suspension into a well plate and store it at 37 ° C, 5% CO ₂ for 24 hours.
Incubated for an hour to create a monolayer of HeLa229 cells. 2. The test compound was prepared at various concentrations using EMEM. 3. C. trachomatis (D / UW-3 / cx
Strain) was prepared to a concentration of 1 × 10 ⁴ (IFU / mL) using EMEM having various concentrations of the test compound. 4. HeLa 229 cell monolayers containing 1 × 10 ⁴ (IFU / mL) C.I.
0.2 mL per well of trachomatis (D / UW-3 / cx strain) solution was added and incubated for 120 minutes. 5. C. EMEM containing trachomatis and the test compound was removed from the well, and 1 mL of EMEM was added to each well. 6. The HeLa229 cell monolayer treated as described above was incubated for 3 days under the conditions of 37 ° C. and 5% CO ₂ . 7. Fluorescence (FITC)
C. using a Chlamydia fluorescence-labeled antibody (Chlamydia FA reagent: manufactured by Denka Seiken Co., Ltd.), which is a genus-specific monoclonal antibody against Chlamydia that is labeled with C. Inclusion bodies of Trachomatis were immunofluorescently stained. 8. For each well, the HeLa229 cell monolayer was observed by fluorescence microscopy and the number of inclusions in the 0.15 mm ² compartment was counted. This operation was performed at arbitrary 30 points per well. For each concentration of the test compound, the above-mentioned test was conducted in 4 wells, and for each of the 4 wells of the same concentration, a section of 0.15 mm ²
The number of inclusion bodies at 30 locations was counted and the total number of inclusion bodies counted in each of the four wells (ie, 0.
The number of inclusion bodies counted by observing 120 sections (total 18 mm ² ) in a section of 15 mm ² was calculated, and C.I. with the test compound in the test was calculated. trachomati
The infection prevention effect of s. Regarding the effect of the test compound, the number of inclusion bodies counted in the four wells by the above-mentioned method in the control group to which the test compound was not added, that is, a section of 0.15 mm ² and 120 sites were observed. The evaluation was also performed as a relative value when the total number of counted inclusion bodies was 100.

Hinokitiol (manufactured by Takasago International Corporation) was used as a test compound, and the final concentration during cell culture was 0 (control), 8, 16, 32, 64, 128 μg / m 2.
The anti-chlamydia effect was evaluated according to the above-mentioned evaluation method by using L as L. The results are shown in Table 2.

[0022]

[Table 2]

As is clear from Table 2, hinokitiol was dosed-dependently at a Hela concentration of 16 μg / mL.
C. to cells It had an inhibitory effect on the infection of trachomatis. That is, it was revealed that tropolone compounds such as hinokitiol can reduce and prevent the infection of chlamydia cells. Further, from the above results, it was revealed that when the tropolone compound is applied to a portion where chlamydia exists during sexual activity, chlamydia infection to a sexual partner who is not infected with chlamydia can be prevented or reduced.

Example 3 Evaluation of anti-Chlamydia action of tropolone compound at and after inoculation of Chlamydia to test cells The anti-Chlamydia action of the test compound was evaluated by the following procedures 1-8. 1. Human cervical cancer cell-derived HeLa229 cells were transferred to Ea
gle's Minimal Essential M
2.5 × 10 ⁵ (c) using edium (EMEM)
cells / mL) and then 24
-Dispense 1 mL / well of the cell suspension into a well plate and store it at 37 ° C, 5% CO ₂ for 24 hours.
Incubated for an hour to create a monolayer of HeLa229 cells. 2. The test compound was prepared at various concentrations using EMEM. 3. C. trachomatis (D / UW-3 / cx
Strain) was prepared to a concentration of 1 × 10 ⁴ (IFU / mL) using EMEM having various concentrations of the test compound. 4. HeLa 229 cell monolayers containing 1 × 10 ⁴ (IFU / mL) C.I.
0.2 mL per well of trachomatis (D / UW-3 / cx strain) solution was added and incubated for 120 minutes. 5. C. EMEM containing trachomatis and test compound was removed from the wells and each well was
1 mL each of EMEM containing test compound at various concentrations
Was added. 6. The HeLa229 cell monolayer treated as described above was incubated for 3 days under the conditions of 37 ° C. and 5% CO ₂ . 7. Fluorescence (FITC)
C. using a Chlamydia fluorescence-labeled antibody (Chlamydia FA reagent: manufactured by Denka Seiken Co., Ltd.), which is a genus-specific monoclonal antibody against Chlamydia that is labeled with C. Inclusion bodies of Trachomatis were immunofluorescently stained. 8. For each well, the HeLa229 cell monolayer was observed by fluorescence microscopy and the number of inclusions in the 0.15 mm ² compartment was counted. This operation was performed at arbitrary 30 points per well. For each concentration of the test compound, the above-mentioned test was conducted in 4 wells, and for each of the 4 wells of the same concentration, a section of 0.15 mm ²
The number of inclusion bodies at 30 locations was counted and the total number of inclusion bodies counted in each of the four wells (ie, 0.
The number of inclusion bodies counted by observing 120 sections (total 18 mm ² ) in a section of 15 mm ² was calculated, and C.I. with the test compound in the test was calculated. trachomati
The infection prevention effect of s. Regarding the effect of the test compound, the number of inclusion bodies counted in four wells by the above method in the control group to which the test compound was not added at the time of inoculation and after inoculation, that is,
The evaluation was also performed as a relative value when the total number of inclusion bodies counted by observing 120 sections in a 0.15 mm ² section was 100.

As a test compound, hinokitiol (manufactured by Takasago International Corporation) was used. The final concentration at the time of inoculation of Trachomatis was 0, 16, 128 μg / mL,
C. the final concentration after trachomatis inoculation is 0,
The anti-chlamydia effect was evaluated according to the above-mentioned evaluation method using 2, 4, 8, 16, and 32 μg / mL, respectively. The results are shown in Table 3.

[0026]

[Table 3] In the table, the numerical values at each concentration are as follows: upper row = total number of inclusion bodies (pieces / 18 mm ² ) lower row = relative value of inclusion bodies (0 μg / mL is 10
0).

As is clear from Table 3, hinokitiol had a dose-dependent anti-chlamydia effect from a concentration of 2 μg / mL after inoculation and from a concentration of 16 μg / mL at the time of inoculation. The continuous use of hinokitiol at the time of inoculation and after inoculation had a superior anti-chlamydia effect as compared with the case of using each alone. In addition, the test method of Example 3 is, for example, a tropolone compound is applied to a sexual activity site by being coated on a condom or as a lubricant for a condom, so that the concentration of the tropolone compound at the site decreases with time after sexual activity. It can be thought of as an imitation of such a case. The results in Table 3 suggest that application of the tropolone compound to a site where chlamydia infection is a problem and residual for a certain period of time are useful for preventing chlamydia infection. Also,
The throat, when the tropolone compound is applied to the site of sexual activity by being coated on a condom or as a lubricant for a condom, or as a prophylactic / therapeutic agent for chlamydia infection,
It is expected that the tropolone compound will remain in the vagina for a long time as compared with the urethra and the like. So in this case
It is naturally suggested that it is also effective in the pharynx and urethra, but in particular, it is suggested that it is effective for secondary infection of newborns and vaginal infection of women that may cause serious problems such as the cause of infertility. To be done.

[0028]

Since the condom of the present invention is coated with the tropolone compound, it is possible to prevent the condom from being damaged or detached.
Even if a chlamydia infection-preventing effect based on the structure of a condom cannot be achieved, the action of a tropolone compound has an advantageous effect of effectively preventing chlamydia infection during intercourse. In addition, the lubricant for condom of the present invention also has an advantageous effect that when applied to a condom, it can effectively prevent chlamydia infection during intercourse. Further, the condom of the present invention and the lubricant for condoms are used at the time of sexual intercourse, so that for a Chlamydia-infected person, the tropolone compound is applied to a portion where Chlamydia-infected cells are present,
It has an advantageous effect that the chlamydia infection of the infected person can be reduced and treated. In addition, the tropolone compound has an advantageous effect of preventing and reducing chlamydia infection in a sexual partner who is not infected with chlamydia by the action of controlling chlamydia in chlamydia-infected cells and direct control of chlamydia. Furthermore, since the condom and the lubricant for condom of the present invention are used at the time of intercourse, it enables application of the tropolone compound to a site where chlamydia infection is a problem and remains for a certain period of time. It has an advantageous effect that it is effective for vaginal infection of a woman who is considered to have a long residual time of the tropolone compound, which may cause serious problems such as secondary infection of A. and infertility. Also, if you have a subclinical infection with Chlamydia, do not notice the infection,
It often passes for a long time as it is, and as a result, there is a serious problem of becoming infertile due to chronic infection. In such a case, since the infected person is not aware of it, the treatment with the chlamydia therapeutic agent is not performed with the intention of performing the treatment. However, even in such a case, as long as the condom and the lubricant for a condom of the present invention are used, the infected person does not notice the infection,
It has the beneficial effect that chlamydia infections can be treated without being aware of the need for treatment. Moreover, the preventive / therapeutic agent for chlamydia infection of the present invention has an advantageous effect that it can prevent and / or treat chlamydia infection.

─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. ⁷ Identification code FI theme code (reference) C10M 159/08 C10N 30:16 // C10N 30:16 40:00 Z 40:00 50:10 50:10 A61F 5/43 (71) Applicant 000236665 Fuji Latex Co., Ltd. 3-19 Kandanishikicho, Chiyoda-ku, Tokyo 1 (72) Inventor Toshio Kishimoto 7-2 Akamatsucho, Chigasaki-shi, Kanagawa Chigasaki Housing 7-403 (72) Inventor Tsutomu Yamazaki 7-10-6 Kitamachi, Nerima-ku, Tokyo (72) Inventor Takashi Kimura 2447-11 Tsukigi, Fujishiro-machi, Kitasoma-gun, Ibaraki Prefecture Inventor Hiroaki Yamano 150 Kokufu-cho, Tochigi-shi, Tochigi Fuji Latte Cos Co., Ltd. (72) Inventor Eiji Kanamaru 150 Kokufucho, Tochigi City, Tochigi Prefecture Fuji Latex Co., Ltd. (72) Inventor Sadazo Gunji 150 Kofucho, Tochigi City, Tochigi Prefecture Fuji Latex In-house F-term (reference) 4C088 AB03 AC02 BA08 BA31 CA03 MA28 MA63 NA10 NA14 ZB35 4C098 AA06 EE11 4C206 AA01 AA02 CB25 KA01 KA18 MA01 MA04 MA48 MA83 NA10 NA14 ZB35 4H104 BB12C DA06C LA08 PA50 QA12 RA01

Claims (9)

[Claims] 1. A condom coated with a tropolone compound. 2. A condom coated with an acidic oil component containing a tropolone compound extracted from trees. 3. The tropolone compound is hinokitiol, β
Condom according to claim 1 or 2, which is one or more compounds selected from the group consisting of -drabulin and γ-tsuyaprisin. 4. A condom coated with hiba oil. 5. A condom lubricant comprising a tropolone compound. 6. A condom lubricant containing an acidic oil component containing a tropolone compound extracted from trees. 7. The tropolone compound is hinokitiol, β
Lubricants for condoms according to claim 5 or 6, which are one or more compounds selected from the group consisting of drablin and γ-tsuyaprisin. 8. A condom lubricant containing hiba oil. 9. A preventive / therapeutic agent for chlamydia infection containing a tropolone compound as an active ingredient.